FDA reviewer says pull Avandia

(Reuters) - Senior FDA officials say they do not know if Avandia, known generically as rosiglitazone, increases heart-attack risk and are asking the advisory panel if the drug should come off the market or stay with stronger warnings or limits. Panel recommendations are expected on Monday afternoon.




Graham, a scientist in the FDA office that monitors the safety of medicines after approval, has been outspoken about drug risks and publicly criticized top FDA officials for failing to respond to warning signs with various medicines.


Read more at Reuters.com Business News